P. Pancheri, L. Tarsitani - Vol. 11, March 2005, Issue 1
Testo Immagini Bibliografia Summary Indice
Nuovo approccio alla terapia antipsicotica:
un agonista parziale D2-5HT1A
A new approach to antipsychotic therapy: a D2-5HT1A partial agonist
1 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
2 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
3 Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology Berl 1989;99:S18-27.
4 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
5 Church SM, Cotter D, Bramon E, Murray RM. Does schizophrenia result from developmental or degenerative processes? J Neural Transm Suppl 2002;63:129-47.
6 Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-86.
7 Thompson LW. The dopamine hypothesis of schizophrenia. Perspect Psychiatr Care 1990;26:18-23.
8 Joyce JN. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology Berl 1993;112(Suppl 1):S16-34.
9 Farde L. Brain imaging of schizophrenia – the dopamine hypothesis. Schizophr Res 1997;28:157-62.
10 Caforio G, Bertolino A. La disregolazione dopaminergica nella schizofrenia. Giornale Italiano di Psicopatologia 2004;10:1-10.
11 Willner P. The dopamine hypothesis of schizophrenia: current status, future prospects. Int Clin Psychopharmacol 1997;12:297-308.
12 Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002;109:411-20.
13 de Bartolomeis A, Tomasetti C. Schizofrenia e disregolazione dopaminergica cortico-sottocorticale: basi molecolari e correlati clinici dell’agonismo parziale dopaminergico come strategia terapeutica. Giornale Italiano di Psicopatologia 2003;9:342-55.
14 Clark D, Hjorth S, Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 1985;62:1-52.
15 Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-67.
16 Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Target CNS Neurol Disord 2002;1:141-7.
17 Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
18 Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-59.
19 Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 2004;1003:9-17.
20 Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9.
21 Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-27.
22 Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996;277:137-43.
23 Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-36.
24 Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976:19-76.
25 Stahl SM. Essential Psychopharmacology. New York: Cambridge University Press 1996.
26 Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002;14:123-9.
27 Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 1998;43:2-11.
28 Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A nreceptor. Eur J Pharmacol 2002;441:137-40.
29 Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000;295:853-61.
30 Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(Suppl 2):106S-115S.
31 Olivier B, Pattij T, Wood SJ, Oosting R, Sarnyai Z, Toth M. The 5-HT(1A) receptor knockout mouse and anxiety. Behav Pharmacol 2001;12:439-50.
32 De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol 2004;14:487-95.
33 Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol 2002;22:206-10.
34 Albert PR, Lemonde S. 5-HT1A Receptors, Gene Repression, and Depression: Guilt by Association. Neuroscientist 2004;10:575-93.
35 Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72.
36 McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharm 2002;5(Suppl 1):S176-S176.
37 Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology Berl 1993;112(Suppl 1):S40-S54.
38 Rao ML, Moller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology 1994;30:160-72.
39 Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87.
40 Mallikaarjun S, Riesgo Y, Salazar D, Bramer S, Xie J, Weston IE. Effect of time of dosing and food on aripiprazole pharmacokinetics. Poster presented at: Twelfth Biennal Winter Workshop on Schizophrenia, February 7-13, Davos, Switzerland, 2004.
41 Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers. Poster presented at: National Institute of Mental Health 42nd Annual National Clinical Drug Evaluation Unit Meeting; June 10-13, Boca Raton, Fla, 2002.
42 Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: Phase 2 clinical trial results. Abstract. Eur Neuropsychopharmacol 1997;7(Suppl 2):S227.
43 Daniel DG, Saha AR, Ingenito G, et al.Aripiprazole, a novel antipsychotic: Overview of a phase II study result. Abstract. Int J Neuropsychopharmacol 2000;3(Suppl 1):S157.
44 Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
45 Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
46 US FDA Center for Drug Evaluation and Research. Medical Review (s) Part 1-4: review and evaluation of clinical data NDA #21-436. Avalilable online at: http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm
47 Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36.
48 Lieberman J, Carson WH, Saha A, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Abstract. Int J Neuropsychopharmacol 2002;5(Suppl 1):S186.
49 Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37.
50 Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
51 Kane JM, Carson WH, Kujawa MJ, et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
52 Kane JM, McQuade R, Jody D, Carson W, Kujawa M, et al. Aripiprazole in treatment resistant schizophrenia: a 6 week, double blind comparison study with perfenazine. Poster presented at: 12 Biennal Winter Workshop on schizophrenia, Davos, Switzerland, February 7-13 2004.
53 Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
54 Bourin M, Auby P, Swanink R, et al. Aripiprazole vs haloperidol for maintained treatment effect in acute mania. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
55 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
56 Guy W. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health 1976, pp. 218-222.
57 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
58 DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-66.
59 Montgomery S, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134;382-9.
60 Heinrich DW, Hanlon TE, Carpenter WT. Quality of Life scale: an instrument for rating the schizophrenic deficit scale. Schiz Bull 1984;10:388-98.
61 Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology Berl 2003;166:391-9.
62 Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.
63 Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-71.
64 De Deyn P, Jeste D, Auby P, Aripiprazole for psychosis of Alzheimer’s disease. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
65 Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11.
66 Worthington JW, Fava M, Hughes ME, et al. Aripiprazole as an augmentor of SSRIs in mood and anxiety disorder patients. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
67 Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1347-8.
68 Findling RL, Blumer J, Kauffman R, et al. Pharmacokinetic and pharmacodynamic effects of aripiprazole in conduct disorder. Poster presented at: 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry; Miami Beach, Florida. October 14-19, 2003.
69 Peralta V, Cuesta MJ. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001;49:269-85.
70 American Psychiatric Association. (DSM-IV-TR) Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Press, Inc. 2000.
71 Pancheri P. Approccio dimensionale e approccio categoriale alla diagnosi psichiatrica. Giornale Italiano di Psicopatologia 1995;1-3:8-23.
72 Archibald DG, Kostic D, Manos G, Stock EG, Jody DN, et al. Effects of long-term aripiprzole therapy on the negative symptoms of schizophrenia. Poster presented at: Twelfth Biennal Winter Workshop on Schizophrenia, Davos, Switzerland; February 7-13, 2004.
73 Manos G, Stock EG, Jody D, et al. Long-term effects ofaripiprazole on the negative symptoms of schizophrenia. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
74 Carson W, Cornblatt B, Saha A, Ali M, Kern R, Green M. Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. Eur Neuropsychopharmacol 2002a;12:S291-S291(abstr).
75 Stock EG, Archibald DG, Tourkodimitris S, Kujawa MJ, et al. Long-term effects of aripiprazolo and haloperidol on affective symptoms of schizophrenia. Poster presented at: Twelfth Biennal Winter Workshop on Schizophrenia, Davos, Switzerland; February 7-13, 2004.
76 Carson WH, Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull 2004;38:38-45.
77 Carson WH, Archibald DG, Manos G, Marcus PN, Kostic D, Stock EG. Short-term efficacy of aripiprazole on depression and anxiety in schizophrenia. APA Annual Meeting, San Francisco, Abstracts NR 2003; 205.
78 Marcus R, Kostic D, Stringfellow J, Hardy S, et al. Effects of short- and long-term aripiprazole treatment on the excitement/hostility symptoms of schizophrenia. Poster presented at: Twelfth Biennal Winter Workshop on Schizophrenia, Davos, Switzerland; February 7-13, 2004.
79 Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
80 Weiden PJ, Waldeck R, Tafesse E, et al. Aripiprazole is not associated with increased diabetes risk: A longterm model. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
81 Jody D, Saha A, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole. Eur Neuropsychopharmacol 2002;12:S290(abstr).
82 McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A Comparison of Weight Change During Treatment With Olanzapine or Aripiprazole: Results From a Randomized, Double-Blind Study. J Clin Psychiatry 2004;65(Suppl 18):47-56.
83 McQuade RD, Jody D, Kujawa MJ, et al. Long-term weight effects of aripiprazole versus olanzapine. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
84 Darlene J, McQuade RD, Kujawa MJ, Carson WH, Iwamoto T, Archibald DG, et al. Long-term effects of aripirazole vs. olanzapine. Poster presented at: Twelfth Biennal Winter Workshop on Schizophrenia, Davos, Switzerland; February 7-13, 2004.
85 Casey DE, L'Italien G, Waldeck R, et al. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; San Francisco, California; May 17-22, 2003.
86 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
87 Weiden P, Waldeck R, Tafesse E. Projected risk of coronar heart disease in schizophrenia: a comparison between aripiprazole and olanzapine [abstract no. 729-P]. Diabetes 2003;52(Suppl 1):A170.
88 McGorry PD, Phillips LJ, Yung AR, Francey S, Germano D, Bravin J, et al. A randomized controlled trial of interventions in the pre-psychotic phase of psychotic disorders. Schizopr Res 2000;41:9-16.
89 McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-8.
90 McGorry PD, Jackson H. The recognition and management of early psychosis: a preventive approach. UK: Cambridge University Press 1999.
91 Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first episode schizophrenia. Am J Psychiatry 2000;157:514-20.
92 Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology Berl 2002;162:42-9.